» Articles » PMID: 20007929

Nontuberculous Pulmonary Mycobacteriosis in Denmark: Incidence and Prognostic Factors

Overview
Specialty Critical Care
Date 2009 Dec 17
PMID 20007929
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Few population-based data are available regarding nontuberculous mycobacteria (NTM) pulmonary disease epidemiology and prognosis.

Objectives: To examine NTM pulmonary colonization incidence, disease incidence, and prognostic factors.

Methods: All adults in Denmark with at least one NTM-positive pulmonary specimen during 1997 to 2008 were identified using national medical databases and were categorized as having possible or definite NTM disease or colonization.

Measurements And Main Results: We calculated annual age-standardized NTM incidence rates and adjusted hazard ratios (HR) of death associated with patient age, sex, comorbidity, NTM species, and NTM disease status. Of 1,282 adults with 2,666 NTM-positive pulmonary specimens, 335 (26%) had definite NTM disease, 238 (19%) possible disease, and 709 (55%) colonization only. NTM incidence rates decreased until 2002, followed by an increase from 2003 to 2008 (mean annual rate per 100,000 person-years: NTM colonization, 1.36; NTM disease, 1.08). Five-year mortality after definite NTM disease was 40.1%. After controlling for potential confounders, 5-year mortality for definite NTM disease was slightly higher than for NTM colonization (adjusted hazard ratio [HR], 1.15; 95% confidence interval [CI], 0.90-1.51). Mycobacterium xenopi was associated with worse prognosis (adjusted HR, 1.51; 95% CI, 0.99-2.33) than the reference Mycobacterium avium complex. High comorbidity level (HR, 2.97), age greater than or equal to 65 years (HR, 9.17), and male sex (female sex HR, 0.73) were predictors of death.

Conclusions: NTM disease incidence has remained unchanged in Denmark over the past 12 years. Patients with NTM colonization and disease have similarly poor prognosis. Negative prognostic factors include high levels of comorbidity, advanced age, male sex, and M. xenopi.

Citing Articles

A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.

Lange C, Bothamley G, Gunther G, Guglielmetti L, Kontsevaya I, Kuksa L Pathog Immun. 2025; 10(2):1-45.

PMID: 40062355 PMC: 11888605. DOI: 10.20411/pai.v10i2.791.


Clinical Significance, Species Distribution, and Temporal Trends of Nontuberculous Mycobacteria, Denmark, 1991-2022.

Dahl V, Pedersen A, Norman A, Rasmussen E, van Ingen J, Andersen A Emerg Infect Dis. 2024; 30(9):1755-1762.

PMID: 39173666 PMC: 11346989. DOI: 10.3201/eid3009.240095.


Treatment for non-tuberculous mycobacteria: challenges and prospects.

Conyers L, Saunders B Front Microbiol. 2024; 15:1394220.

PMID: 38887711 PMC: 11180805. DOI: 10.3389/fmicb.2024.1394220.


Treatable traits and challenges in the clinical management of non-tuberculous mycobacteria lung disease in people with cystic fibrosis.

Gramegna A, Misuraca S, Lombardi A, Premuda C, Barone I, Ori M Respir Res. 2023; 24(1):316.

PMID: 38104098 PMC: 10725605. DOI: 10.1186/s12931-023-02612-1.


Real-World Data Collection from Expanded Access Case Studies for the Treatment of Nontuberculous Mycobacterial Infection with Clofazimine.

Gravelin M, Nguyen T, Davies M, Richards B, Sexton J, Gregg K medRxiv. 2023; .

PMID: 37961189 PMC: 10635239. DOI: 10.1101/2023.10.30.23297757.